Kailos Genetics Announces Strategic Investment and Partnership with In-Q-Tel

Partnership will further develop Kailos’ leading-edge next-generation sequencing solutions for the intelligence community July 11, 2017 09:00 AM Eastern Daylight Time HUNTSVILLE, Ala.–(BUSINESS WIRE)–Kailos Genetics, a personalized medicine company offering a leading-edge suite of tools for next-generation sequencing (NGS)-based assays, today announced a strategic partnership with and investment from In-Q-Tel, Inc. (IQT). IQT is the... Read more

FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers

Basel, 23 June 2017 FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers Treatment can be administered in five to seven minutes, compared to 1.5 hours or more for intravenous Rituxan* Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved Rituxan... Read more

PacBio Technology Resolves Complex Maize Genome, Driving Demand for Other Large-Scale AgBio Sequencing Projects

MENLO PARK, Calif., June 22, 2017 (GLOBE NEWSWIRE) — A new publication in Nature reveals the significant quality improvement afforded by Single Molecule, Real-Time (SMRT®) Sequencing for the maize genome, with implications for other complex crop and livestock genomes. This new PacBio® genome assembly, produced by scientists at Cold Spring Harbor Laboratory, the USDA’s Agricultural Research... Read more

PacBio Technology Resolves Complex Maize Genome, Driving Demand for Other Large-Scale AgBio Sequencing Projects

MENLO PARK, Calif., June 22, 2017 (GLOBE NEWSWIRE) — A new publication in Nature reveals the significant quality improvement afforded by Single Molecule, Real-Time (SMRT®) Sequencing for the maize genome, with implications for other complex crop and livestock genomes. This new PacBio® genome assembly, produced by scientists at Cold Spring Harbor Laboratory, the USDA’s Agricultural Research... Read more

BD Receives FDA 510(k) Clearance for New Line of Customizable, 3.0mm Micro-Laparoscopic Instruments

FRANKLIN LAKES, N.J., June 20, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its new line of Snowden-Pencer™ 3.0mm laparoscopic ergonomic take-apart instruments received U.S. Food and Drug Administration (FDA) 510(k) clearance for use in laparoscopic surgery. The new line of Snowden-Pencer 3.0mm laparoscopic... Read more

Unique Mass Spectrometer for Analysis of Semiconductor Process Gases

June 15, 2017, Peabody, Mass. — The JEOL InfiTOF compact high-resolution gas analysis mass spectrometer is ideal for monitoring trace impurities in semiconductor process gases, evolved gases from catalytic reactions, vapor epitaxy and more.  No larger than a desktop PC, the InfiTOF instantly separates isobaric gases such CO and N2, or N2O and CO2, for... Read more

MTS Systems Awards Endowment to Michigan Technological University in Honor of PCB Founders Jim and Bob Lally

EDEN PRAIRIE, MN, June 13, 2017 /PRNewswire/ — MTS Systems Corporation (NASDAQ: MTSC), a leading global supplier of high-performance test and measurement systems and sensors, today announced establishment of the ‘James and Robert Lally Endowment’ at Michigan Technological University.  This $1 million endowment was given in honor of the pioneering efforts of the Lallys in the... Read more

Collaboration Between Shimadzu, The Systems Biology Institute, and Osaka University Starting the Provision of an Open Platform Multi-omics Data Analysis Pack

Research for creating substances with advanced functions utilizing microorganisms and cells, rather than chemical synthesis, has expanded in recent years in a variety of fields, including biofuels, pharmaceuticals, and food products for example. Advancement in gene editing techniques is further creating new avenues of research. In this direction of research, the effect of incorporating genes... Read more

FDA approves Roche’s Actemra/RoActemra (tocilizumab) for giant cell arteritis

Basel, 23 May 2017 FDA approves Roche’s Actemra/RoActemra (tocilizumab) for giant cell arteritis Actemra/RoActemra is the first FDA-approved treatment for adults with giant cell arteritis (GCA) FDA previously granted Priority Review and Breakthrough Therapy Designation for Actemra/RoActemra in GCA Sixth FDA approval for Actemra/RoActemra since its US launch in 2010 Roche (SIX: RO, ROG; OTCQX:... Read more